Enhancing pulmonary delivery and immunomodulation of respiratory diseases through virus-mimicking nanoparticles
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.06.044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Yugo Araújo Martins und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14040-900, Br…. Hauptthemen laut MEDLINE: Nanoparticles, Lung, SARS-CoV-2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 81 Literaturangaben.
Abstract (Originalsprache)
This study introduces the nanobromhexine lipid particle (NBL) platform designed for effective pulmonary drug delivery. Inspired by respiratory virus transport mechanisms, NBL address challenges associated with mucus permeation and inflammation in pulmonary diseases. Composed of low molecular weight polyethylene glycol-coated lipid nanoparticles with bromhexine hydrochloride, NBL exhibit a size of 118 ± 24 nm, a neutral zeta potential, osmolarity of 358 ± 28 mOsmol/kg, and a pH of 6.5. Nebulizing without leakage and showing no toxicity to epithelial cells, NBL display mucoadhesive properties with a 60% mucin-binding efficiency. They effectively traverse the dense mucus layer of Calu-3 cultures in an air-liquid interface, as supported by a 55% decrease in MUC5AC density and a 29% increase in nanoparticles internalization compared to non-exposed cells. In assessing immunomodulatory effects, NBL treatment in SARS-CoV-2-infected lung cells leads to a 40-fold increase in anti-inflammatory MUC1 gene expression, a proportional reduction in pro-inflammatory IL-6 expression, and elevated anti-inflammatory IL-10 expression. These findings suggest a potential mechanism to regulate the excessive IL-6 expression triggered by virus infection. Therefore, the NBL platform demonstrates promising potential for efficient pulmonary drug delivery and immunomodulation, offering a novel approach to addressing mucus permeation and inflammation in pulmonary diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14040-900, Brazil.
- Fundação Oswaldo Cruz - FIOCRUZ, Bi-Institutional Translational Medicine Plataform, Ribeirão Preto, SP 14040-030, Brazil.
- Department of Biochemistry and Imumunology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14049-900, Brazil.
- Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva 1211, Switzerland.
- Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP 14040-900, Brazil. Electronic address: rvianna@fcfrp.usp.br.
Zitieren
APA
Martins, Y. A., Guerra-Gomes, I. C., Rodrigues, T. S., Tapparel, C., & Lopez, R. F. V. (2024). Enhancing pulmonary delivery and immunomodulation of respiratory diseases through virus-mimicking nanoparticles. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.06.044
Vancouver
Martins YA, Guerra-Gomes IC, Rodrigues TS, Tapparel C, Lopez RFV. Enhancing pulmonary delivery and immunomodulation of respiratory diseases through virus-mimicking nanoparticles. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.06.044
BibTeX
@article{Martins2024,
author = {Martins, Yugo Araújo and Guerra-Gomes, Isabel Cristina and Rodrigues, Tamara Silva and Tapparel, Caroline and Lopez, Renata Fonseca Vianna},
title = {Enhancing pulmonary delivery and immunomodulation of respiratory diseases through virus-mimicking nanoparticles},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.06.044}
}
EUVIMED